PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study Of The Efficacy And Safety Of SU-014813 In Patients With Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Breast Neoplasms
- Interventions
- Drug: SU014813
- First Posted Date
- 2006-05-08
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 90
- Registration Number
- NCT00322517
- Locations
- 🇬🇧
Pfizer Investigational Site, London, United Kingdom
Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2006-05-04
- Last Posted Date
- 2010-12-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 43
- Registration Number
- NCT00321815
- Locations
- 🇺🇸
Pfizer Investigational Site, Dalls, Texas, United States
Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer
Phase 2
Terminated
- Conditions
- Carcinoma, Non-Small Cell Lung
- Interventions
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2009-09-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT00321308
- Locations
- 🇮🇹
Pfizer Investigational Site, Torino, Italy
Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer
Phase 2
Completed
- Conditions
- Breast NeoplasmsNeoplasm Metastasis
- Interventions
- Drug: SKI-606 (Bosutinib)
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 75
- Registration Number
- NCT00319254
- Locations
- 🇺🇦
Pfizer Investigational Site, Uzhgorod, Ukraine
Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.
Phase 3
Completed
- Conditions
- SeizuresEpilepsies, PartialEpilepsy, Complex PartialEpilepsy, GeneralizedEpilepsy
- Interventions
- Drug: PlaceboDrug: Vanquix Auto-Injector (Diazepam Injection)
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 234
- Registration Number
- NCT00319501
- Locations
- 🇺🇸
Stein Life Child Neurology Medical Specialists Inc., Irvine, California, United States
🇺🇸Lahey Clinic Medical Center, Burlington, Massachusetts, United States
🇺🇸Morton Plant Hospital Pharmacy, Clearwater, Florida, United States
Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients.
Phase 4
Completed
- Conditions
- Sepsis
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2017-09-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 160
- Registration Number
- NCT00318552
- Locations
- 🇭🇺
Research Site, Veszprem, Hungary
Evaluation of Pancreatic Tissue Penetration of Meronem® in the Prophylaxis of Septic Complications in Severe Pancreatitis
Phase 4
Completed
- Conditions
- Pancreatitis
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2017-09-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT00318994
- Locations
- 🇨🇴
Research Site, Bogota, Colombia
Safety and Efficacy Study of MRE0094 to Treat Large, Single or Multiple, Chronic, Neuropathic, Diabetic Foot Ulcers
Phase 2
Terminated
- Conditions
- Foot Ulcer, DiabeticDiabetes Complications
- Interventions
- Drug: MRE0094Drug: Vehicle gel
- First Posted Date
- 2006-04-26
- Last Posted Date
- 2012-06-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT00318214
- Locations
- 🇺🇸
Associated Foot & Ankle Specialists, LLC, Phoenix, Arizona, United States
🇺🇸Innovative Medical Technologies, Los Angeles, California, United States
🇺🇸University of Miami, Miami, Florida, United States
A Single Dose Study to Evaluate the PK-PD Response and Safety of PHA-794428 in Children With Growth Hormone Deficiency
Phase 2
Terminated
- Conditions
- Growth Hormone Deficiency
- First Posted Date
- 2006-04-17
- Last Posted Date
- 2011-05-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 32
- Registration Number
- NCT00314938
- Locations
- 🇬🇧
Pfizer Investigational Site, Cardiff, United Kingdom
Study Evaluating PD-0299685 for the Treatment of Vasomotor Symptoms (Hot Flashes / Flushes) Associated With Menopause
Phase 2
Completed
- Conditions
- Hot Flashes
- First Posted Date
- 2006-04-17
- Last Posted Date
- 2011-03-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 527
- Registration Number
- NCT00314964
- Locations
- 🇪🇸
Pfizer Investigational Site, Valencia, Spain
© Copyright 2025. All Rights Reserved by MedPath